
Oncology NEWS International
- Oncology NEWS International Vol 18 No 9
- Volume 18
- Issue 9
Avastin wins FDA OK for advanced kidney cancer treatment
Avastin (bevacizumab) plus interferon-alfa has been approved for the treatment of metastatic renal cell carcinoma, according to Genentech. Approval was based on phase III data from the AVOREN study, which showed a 67% increase in progression-free survival (10.2 months) compared to those who received interferon-alfa alone (5.4 months; hazard ratio = 0.60).
Avastin (bevacizumab) plus interferon-alfa has been approved for the treatment of metastatic renal cell carcinoma, according to Genentech. Approval was based on phase III data from the AVOREN study, which showed a 67% increase in progression-free survival (10.2 months) compared to those who received interferon-alfa alone (5.4 months; hazard ratio = 0.60).
Articles in this issue
about 16 years ago
Industry Watchabout 16 years ago
Letter to the Editorabout 16 years ago
Novel chemoRT regimen ups survival in pancreatic caabout 16 years ago
Low expression of MSH2 protein predicts survival in NSCLCabout 16 years ago
Prostate cancer pilot program stresses patient-oriented careabout 16 years ago
CT distinguishes liver cancer mets from lung primaryabout 16 years ago
Prostate cancer patients seek out mind-body careabout 16 years ago
Who's Newsabout 16 years ago
Panitumumab plus FOLFIRI bests FOLFIRI alone as second-line colon ca RxNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































































